{
  "ptid_time": "002_S_4171_2012-02-29",
  "img_path": "/data/qiuhui/data/adni/images/002_S_4171/2012-02-29/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 32,706 mm³, 8.9% above the reference mean. With a Z-score of 0.21 (58.4th percentile), this represents normal volume ; hippocampal volume measures 6,994 mm³, 12.9% below the reference mean. With a Z-score of -1.29 (9.9th percentile), this represents mild atrophy; whole brain volume measures 1,003,370 mm³, 11.6% below the reference mean. With a Z-score of -1.64 (5.1th percentile), this represents moderate atrophy; entorhinal cortex volume measures 2,989 mm³, 29.9% below the reference mean. With a Z-score of -2.07 (1.9th percentile), this represents significant atrophy; fusiform gyrus volume measures 15,821 mm³, 20.5% below the reference mean. With a Z-score of -1.71 (4.4th percentile), this represents moderate atrophy; middle temporal gyrus volume measures 15,871 mm³, 29.2% below the reference mean. With a Z-score of -2.40 (0.8th percentile), this represents significant atrophy. ",
  "text_data": "Age is 69.9 years. Gender is Male. Education: 16 years. MMSE: 28.0. MoCA: 22.0. APOEε4 alleles: 0.0. ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows significant atrophy in key Alzheimer's-related regions (hippocampus, entorhinal cortex, fusiform gyrus, middle temporal gyrus), while cognitive testing reveals a discrepancy between MMSE (normal) and MoCA (mild impairment). The absence of APOE4 reduces genetic risk but does not rule out neurodegeneration.  \n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (likely amnestic subtype given hippocampal/entorhinal atrophy).  \n**Confidence:** **Medium** (high confidence in neurodegeneration based on imaging, but MCI diagnosis is less certain due to near-normal MMSE and lack of detailed clinical history on functional decline).  \n\n*Note: Progression to dementia is likely if atrophy patterns continue, but current cognitive scores don’t meet dementia thresholds. Follow-up with CSF biomarkers or amyloid PET could clarify etiology.*",
  "timestamp": "2025-07-25T20:20:28.207712"
}